IP Library Granted Patent US 8,685,972
Granted Patent B2
US 8,685,972 · App. 13/058,231 · Granted Apr 1, 2014

Pyrimidine derivatives for treatment of alzheimer's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,972
App. No.
13/058,231
Granted
Apr 1, 2014
Kind
B2
Abstract

The invention encompasses pyrimidine derivatives as gamma secretase modulators, useful for treating diseases associated with the deposition of beta-amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases. Pharmaceutical compositions and methods of use are included.

Claims (30)

1. A compound of formula I:

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

W represents CH;

Z represents N;

R 1 and R 2 independently represent H, C 1-4 alkyl, C 1-4 alkoxy, halogen or CF 3 ;

R 4 and R 5 independently represent H or (CH 2 ) m —X, where m is 0 or 1 and X represents halogen, 5- or 6-membered heteroaryl which is optionally substituted with up to 2 C 1-4 alkyl groups, CN, CF 3 , R 6 , OR 6 , N(R 6 ) 2 , SO 2 R 6 , CO 2 R 6 or CON(R 6 ) 2 where each R 6 independently represents H, phenyl, C 1-4 alkyl or hydroxyC 1-4 alkyl or two R 6 groups attached to the same nitrogen optionally complete an N-heterocycle; and

Ar represents a phenyl or 5- or 6-membered heteroaryl ring bearing from 2 to 4 substituents selected from:

(a) C 1-6 alkyl;

(b) C 3-6 cycloalkyl;

(d) C 3-6 cycloalkyl C 1-6 alkyl;

(e) C 2-6 alkenyl;

(f) OR 7 ;

(g) CO 2 R 7 ;

(h) N(R 7 ) 2

(i) SR 7 ; and

(j) CF 3 ;

where each R 7 represents C 1-6 alkyl.

2. A compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, wherein Ar represents:

where R 8 represents C 1-6 alkyl; and R 9 , R 10 and R 11 independently represent:

H;

C 1-6 alkyl;

OR 7 where R 7 represents C 1-6 alkyl;

CO 2 R 7 where R 7 represents C 1-6 alkyl; or

N(R 7 ) 2 where R 7 represents C 1-6 alkyl;

with the proviso that at least one of R 9 and R 10 is other than H and that R 11 is other than H.

3. A compound according to claim 2 of formula II:

or a pharmaceutically acceptable salt or hydrate thereof.

4. A compound according to claim 3 or a pharmaceutically acceptable salt or hydrate thereof, wherein at least one of R 4 and R 5 is H.

5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.

6. A method of treating Alzheimer's disease, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2011
From: RIVKIN, ALEXEY A.; AHEARN, SEAN P.; CHICHETTI, STEPHANIE M.
To: MERCK, SHARP & DOHME CORP.
Reel/Frame 026239/0038 →